 Home > Active Pharmaceutical Ingredients > Inhibitor Drugs > N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine for Sale > Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6 buy - large image1

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6 buy - image1

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6 buy - image2

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6 buy - image3

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6 buy - image4

Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6

Name: Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6
Brand: NATURE
SKU: pr2607062009
Price: 34 USD
Availability: InStock

TDS 272 Inquiries

Unit Price: Get Latest Price 

CAS No.:

1346242-81-6

Grade:

Pharmaceutical Grade

Content:

99%

Port:

Brand:

NATURE

Packaging:

1g,10g,100g,1kg per package

Price valid (until):

2026-08-06

Contact Supplier

 Chat Now

NATURE INDUSTRIAL LIMITED

Company Type:

Trader

Location:

Hongkong, China

Qualification:

Main Products:

Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332

 Visit Store

Product Description
Seller Information
Inquiry History

Description

Erdafitinib raw powder with high quality and good price CAS NO.1346242-81-6

Product Name: ERDAFITINIB
Synonyms: Erdafitinib;Erdafitinib(JNJ-42756493);N-(3,5-dimethoxyphenyl)-N'-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Suftalan Zine;N-(3,5-Dimethoxyphenyl)-N'-isopropyl-N-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;N1-(3,5-dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine
CAS: 1346242-81-6
MF: C25H30N6O2
MW: 446.54
EINECS: 610-261-8

ERDAFITINIB purity

Single impurity	≤ 0.5 %
Water	≤ 0.5 %
HPLC Purity	≥99 %

Our company sells more than tons of API and Intermediate to domestic export trading companies every year.
In recent years, we have started to do foreign market. Please contact me to obtain the factory price.

Shop Hot Selling Erdafitinib Raw Material Powder CAS 1346242-81-6 for Sale-Detailed Image 1

Our services

♦ Competitive prices and high quality products

♦ A dequate inventory and products will be shipped out asap.

♦ Quick and clear response to customers questions.

♦ Comfortable conversation and easy talk

Our Package

Packing:

1. Weight <1kg ---- Fluorinated bottle

2. 25kg ---- Plastic bucket

3. 180- 200kg ---- Drum

P.S.: we accept packaging customization.

Delivery:

We have large quantity raw powder in stock, normally could ship out within 3 working days.
For rush delivery, please contact our sales team for particular arrangement.

Shipping:

We ship goods via DHL, Fedex, UPS, TNT, China post, NL Post and other couriers, weight from 10g to 1000kg or even bulker.
Shipping details & shipping documents will be provided and sent to customers as long as it is ready.
We keep tracking the shippment until clients well received.
After years export shipping experience, with professional and experienced cooperated forwarders, we ensure that goods can be delivered in multiple ways safetly and efficiently.

Package

Powder: PE bag, glass bottle, or PTFE bottle for inner packing, and aluminum foil bag for outer packing.

Bulk order: Fiber drum or steel drum.
Custom packaging

Payment options

T/T,Paypal,Visa,L/C or according to your needs.

Transportation

UPS,TNT,EMS,Fedex,and so on.Based on your location, the goods will be safely cleared and delivered to your doorstep within 3 to 7 days in Europe and the United States.

Shop High purity Apixaban Powder producer CAS 503612-47-3-Detailed Image 2

Shop Hot Selling Erdafitinib Raw Material Powder CAS 1346242-81-6 for Sale-Detailed Image 3

Shipping information

by courier,by sea,by air etc

Shop Retatrutide in vial package for weight loss-Detailed Image 4

Shop Customized 10MG 30MG 60MG 100MG Tirzepatide weight loss Retatrutide-Detailed Image 4

our company

Natrue is a high-end brand company focusing on the biomedical industry and integrating R&D, production and sales. It has an independent R&D center, advanced laboratory equipment and a professional R&D team, a GMP standard production workshop, a complete set of internationally advanced assembly line equipment, a preparation workshop with a cleanliness level of 100,000, as well as sophisticated testing instruments and scientific testing methods, providing solid technical support for the production of high-quality products. Through long-term R&D, production, and sales practices, it has formed its own unique product line, providing users with products of reliable quality at highly affordable prices. We strictly control quality, ensure the stability of product quality in all aspects, and win the trust of customers with high quality and high-level development.

Our team of experienced professionals is committed to delivering innovative solutions and exceptional customer service. We work closely with our clients to understand their unique needs and develop customized products to meet their specific requirements. With a state-of-the-art manufacturing facility and strict quality control measures, we ensure that our products meet the highest standards of safety and purity.

We have been keeping providing new products to the markets of Europe,America,Australia,Japan and South-east Asia,etc. We always insist on our company's principle or quality & credit are first"and after several years of development,we have enjoyed good reputation in the fitness industry.

We try our best to provide first-class goods,competitive price and supreme service to meet every client's requirements. We look forward to establish a long-term business relationship with you on the basis of equality and mutual benefits.

Shop Hot sale high quality Spermine Dihydrate Powder CAS 403982-64-9 spermine dihydrate-Detailed Image 6

Shop Wholesale High Quality Erdafitinib Raw Material Powder CAS 1346242-81-6 API Powder-Detailed Image 7

Shop Customized 10MG 30MG 60MG 100MG Tirzepatide weight loss Retatrutide-Detailed Image 7

Shop Cosmetic Grade Pharma Grade Tranexamic Acid-Detailed Image 5

Shop Hot Selling Erdafitinib Raw Material Powder CAS 1346242-81-6 for Sale-Detailed Image 10

FAQ

Q1: Are you the manufacturer or trade company?
--We are the manufacturer in China, founded on 2011.

Q2: When will the product be shipped after payment?
--The parcel will be get ready and shipped within 1 day.

Q3: How long will it take to receive the parcel?
--3-5days for the US market; 3-7days for the others.

Q4: What can I do if I don't have the ability to clear the custom.
--We got experience after doing export for many years, so don't worry we can handle that.

Q5: Can I get a sample before placing an order?
--We got experience after doing export for many years, so don't worry we can handle that.

Q6: How to place an order for each product?
--Please send us an inquiry and let us know your requirements; we will send you a complete quotation including freight, confirm the order and send payment/deposit, we will arrange production or delivery of the goods after receiving the bank receipt.

ECHEMI Editorial Reference

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy. Erdafitinib's innovation lies in the fact that it is the first personalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the design of erdafitinib in developing more personalized and precision medicines with the capacity to target cancer treatment to a patient's specific genetic mutation. Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a welcome new option in the ever-expanding therapeutic tool kit to treat such prevalent medical conditions. Nevertheless, although erdafitinib was granted Breakthrough Therapy designation and Accelerated Approval from the FDA so as to allow the agency to focus on and expedite the approval process for a medication indicated for a serious condition that fills an unmet medical need using clinical trial data that is believed to predict a genuine clinical benefit for patients with the given condition, such designations mean further ongoing clinical trials are necessary to confirm the clinical benefit of erdafitinib going forward.|Erdafitinib is an oral small molecule inhibitor of fibroblast growth factor receptors (FGFR) 1 to 4 that is used in the therapy of locally advanced, unresectable or metastatic urothelial carcinoma. Erdafitinib has been associated with a high rate of serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent acute liver injury.|Erdafitinib is an orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Upon oral administration, erdafitinib binds to and inhibits FGFR, which may result in the inhibition of FGFR-related signal transduction pathways and thus the inhibition of tumor cell proliferation and tumor cell death in FGFR-overexpressing tumor cells. FGFR, upregulated in many tumor cell types, is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival.

Certificates

Basic Info

Product Name:

N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine

Other Name:

1,2-Ethanediamine,N1-(3,5-dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-;N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine;Erdafitinib;JNJ 42756493;Balversa;1620332-47-9

CAS No.:

1346242-81-6

Molecular Formula:

C25H30N6O2

InChIKeys:

InChIKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N

Molecular Weight:

446.54

Exact Mass:

446.54

UNII:

890E37NHMV

NCI Thesaurus Code:

C103273

ATC Code:

L - Antineoplastic and immunomodulating agents

Categories:

Inhibitor Drugs

Characteristics

PSA:

77.3

XLogP3:

3.2

Density:

1.2±0.1 g/cm3

Flash Point:

354.4±31.5 °C

Refractive Index:

1.618

Water Solubility:

<1 mg/mL

Research

Class:

Pan-FGFR tyrosine kinase inhibitor (FGFR1-4); antineoplastic (ATC L01EN01)

Status:

Approved (FDA accelerated approval 2019-04-12; converted to regular approval 2024-01-19; EMA approval 2024-08)

Mechanism:

Erdafitinib is an orally bioavailable, functionally selective small-molecule inhibitor of fibroblast growth factor receptors 1-4 (FGFR1-4). It inhibits FGFR tyrosine kinase activity (IC50 1.2-5.7 nM), blocking downstream RAS-MAPK/ERK and PI3K-AKT signaling that drives proliferation and survival of tumor cells harboring activating FGFR alterations (mutations, amplifications, or fusions). Rapid lysosomal uptake contributes to prolonged inhibition of FGFR signaling.

EC50 (Fgfr1 Ic50):

1.2 nM

EC50 (Fgfr3 Ic50):

3.0 nM

EC50 (Fgfr2 Ic50):

2.5 nM

EC50 (Fgfr4 Ic50):

5.7 nM

EC50 (Vegfr2 Ic50):

36.8 nM (approximately 30-fold selectivity vs FGFR1)

Source:

Perera TPS, et al. Mol Cancer Ther. 2017;16(6):1010-1020.DOI

Clinical Development:

NCT02365597; NCT03390504

FDA:

Balversa (approved 2019-04-12)

References

ChEMBL:

DrugBank:

KEGG DRUG:

PubChem:

Literature:

FDA: Approval announcement 2024-01-19; FDA: BALVERSA label (NDA 212018, BLC2001); NEJM: Loriot et al. (2023) — THOR Cohort 1; NEJM: Loriot et al. (2019) — BLC2001; Mol Cancer Ther: Perera et al. (2017) — discovery pharmacology

Disclaimer:

Erdafitinib (Balversa) is a prescription medicine approved by the US FDA and the EMA for specific oncology indications. ECHEMI lists this product for industrial sourcing and supply-chain reference only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or a substitute for approved therapy. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

See More N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine Properties 

Hazard Identification

Classification of the substance or mixture

Acute toxicity - Category 4, Oral

Skin sensitization, Sub-category 1B

Serious eye damage, Category 1

Reproductive toxicity, Category 2

Specific target organ toxicity â repeated exposure, Category 1

GHS label elements, including precautionary statements

Precautionary statement(s)
Pictogram(s)
Signal word	Danger
Hazard statement(s)	H302 Harmful if swallowed H317 May cause an allergic skin reaction H318 Causes serious eye damage H361 Suspected of damaging fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P261 Avoid breathing dust/fume/gas/mist/vapours/spray. P272 Contaminated work clothing should not be allowed out of the workplace. P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/... P203 Obtain, read and follow all safety instructions before use. P260 Do not breathe dust/fume/gas/mist/vapours/spray.
Response	P301+P317 IF SWALLOWED: Get medical help. P330 Rinse mouth. P302+P352 IF ON SKIN: Wash with plenty of water/... P333+P317 If skin irritation or rash occurs: Get medical help. P321 Specific treatment (see ... on this label). P362+P364 Take off contaminated clothing and wash it before reuse. P305+P354+P338 IF IN EYES: Immediately rinse with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P317 Get medical help. P318 IF exposed or concerned, get medical advice. P319 Get medical help if you feel unwell.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.

Other hazards which do not result in classification

no data available

Handling and Storage

Precautions for safe handling

Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.

Conditions for safe storage, including any incompatibilities

Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.

See More N1-(3,5-Dimethoxyphenyl)-N2-(1-methylethyl)-N1-[3-(1-methyl-1H-pyrazol-4-yl)-6-quinoxalinyl]-1,2-ethanediamine Safety Data Sheet 

Seller Information

Business Type:
Trader

Main Products:
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332

Location:
Unit D01,3/F., Wong King Industrial Building,No.2 Tai Yau Street, Kowloon

Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance

Average lead Time:
7

Total Annual Revenue:
$50 million-$100 million

Total Employees:
51-100

Year of Establishment:
2012

We have more than 10 years experience in the pharmacy filed. Mainly manufactures pharmaceutical APIs,Pharmaceutical intermediate and Cosmetic raw material. Owing to the good quality and competitive price, we have a very good reputation in China's pharmaceutical circles.

In the principle of "Quality Oriented", Jianfeng passed the certification of ISO9001:2008 Quality Management System.

Our products are based on bulk, high volume, wholesale price, third party testing, certificate reporting, and bring high quality ingredients to many domestic and overseas enterprises.

"Honesty, practicality, innovation, development" are our values. Jianfeng would like to cooperate with you with high quality products and competitive price.

Inquiry History

272 Inquiries

Country	Product	Purchase Quantity	Date Posted
Germany	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 25, 2026
Vietnam	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 18, 2026
United States	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 26, 2026
Australia	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Aug 14, 2026
Poland	High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib	1 G	Jul 28, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Sep 1, 2026
Canada	Best Price Pure 98% HPLC JNJ-42756493 Erdafitinib Powder CAS 1346242-81-6	500 MG	Aug 25, 2026
United Kingdom	Factory Direct Supply Erdafitinib Raw Powder 98% Purity Erdafitinib Powder 1346242-81-6	1 MT	Sep 4, 2026
United States	Factory Supply Erdafitinib CAS 1346242-81-6 99% High Purity FGFR Inhibitor API Powder	1 G	Sep 3, 2026
United States	Hot Selling ERDAFITINIB 1346242-81-6 Factory Supply Raw Materials High Qulity Wholesale price	3 MT	Jul 5, 2026
Australia	Erdafitinib	1 G	Jul 18, 2026
Germany	Erdafitinib	500 MG	Jul 28, 2026
Cyprus	Erdafitinib	1 G	Jul 22, 2026
Bulgaria	Erdafitinib	500 MG	Jun 18, 2026
Switzerland	1g Erdafitinib raw powder >99% purity	1 G	May 22, 2026
United States	Erdafitinib	1 G	Aug 27, 2026
Georgia	Erdafitinib	1 G	Aug 19, 2026
United States	Erdafitinib	1 G	Aug 29, 2026
United States	erdafitinib	1 G	Sep 6, 2026
Canada	Erdafitinib	1 G	Sep 4, 2026

Go to Page

Post an enquiry for this product

More Choices Find All Products for Sale 

Product Name	Grade / Content	Price	Supplier Name	Details
Erdafitinib 99% CAS.1346242-81-6 High Purity/ DDP/ Low MOQ	Pharmaceutical Grade/99		Hainan Flying International Trade Co., L	Inquiry
High Quality Erdafitinib 99% powder 1346242-81-6 Erdafitinib powder	Pharmaceutical Grade/99		Fulecare	Inquiry
High Quality Erdafitinib 99% powder 1346242-81-6-Shaanxi Dideu Medichem Co.Ltd	Chemical Grade/99	$1/G FOB	Shaanxi Dideu Medichem Co. Ltd	Inquiry
ERDAFITINIB high quality	/	$1-1.3/BOU FOB	Nanjing Paron Technology Co., Ltd	Inquiry
N1-(3,5-Dimethoxyphenyl)-N2-isopropyl-N1-(3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl)ethane-1,2-diamine 99%	/		Conier Chem&Pharma Limited	Inquiry